Functional GSTA1 Haplotypes Affect Clearance and Toxicity of Busulfan When Administered in 16 Doses to Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Multicenter Prospective Study on Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Authors: Ansari Marc , Huezo-Diaz Patricia , Uppugunduri Chakradhara Rao Satyanarayana , Nava Tiago , Rezgui Mohammed Aziz , Mlakar Vid , Lesne Laurence , Theoret Yves , Chalandon Yves , Dupuis L Lee , Schechter Tal , Bartelink Imke H , Boelens Jaap Jan , Bredius R.G.M. , Dalle Jean-Hugues , Azarnoush Saba , Sedlacek Petr , Lewis Victor A. , Champagne Martin , Peters Christina , Bittencourt Henrique , Krajinovic Maja 
Published: October 2019

Busulfan (BU) dose adjustment following therapeutic drug monitoring (TDM) contributes to better outcome of hematopoietic stem cell transplantation (HSCT). The therapeutic target window can be reached in approximately 51% to 74% of pediatric cases and 45% to 64% of infants depending on the dosing guideline used. We hypothesize that a higher proportion of pediatric patients could achieve the target BU area-under-the-curve (AUC) of 900-1500 µM.min per dose in a four times dosing schedule through genotype-guided initial BU dosing. Previous investigations by our group and others showed association of glutathione -S- transferase alpha 1 (GSTA1) with reduced BU clearance (CL), likely due to altered expression of GSTA1 enzyme, principally involved in BU metabolism.

To delineate and investigate the association of each GSTA1 haplotype with the CL of BU, promoter haplotypes of GSTA1 gene were assessed in vitro with reporter gene-assay and clinically in a pediatric multi-center study (N =138) through association with BU CL, AUC, dose change and clinical outcomes. All patients received BU based myeloablative conditioning regimen. BU PK parameters from 1st dose were estimated and further doses were adjusted to have a steady state concentrations of 600-900 ng/mL and GSTA1promoter SNPs at -69, -513, -631, -1142 positions were genotyped using allele specific oligo hybridization method.

Reporter-gene assays confirmed significant differences between the haplotype subgroups and supported their importance in capturing PK variability. Four GSTA1 diplotype groups (I-IV) that significantly correlated with CL (p=0.009) were distinguished. GSTA1 diplotypes (group I) underlying fast metabolizing capacity (*A2*A2&*A2*A3) had lower cumulative AUC and a higher dose increase after TDM whereas those with slow metabolizing capacity (group IV, *B1a*B1a /*B1a*B1b /*B2*B1a / *A1*B1b)had highest AUC and least dose change (p=0.02). Multivariate linear model included GSTA1 diplotype groups and non-genetic factors such as age, gender, first BU dose in mg/kg and patients origin. Dose (p<0.0005), gender (p=0.05) and GSTA1 diplotypes (p=0.01) were retained in the final model that explained 34% of overall variability. Analysis with clinical outcomes indicated higher incidences of sinusoidal obstruction syndrome in Group IV diplotype carriers (HR=7.1; 95% CI: 2.5-20.4) compared to patients with other GSTA1diplotypes. A similar association was also seen with acute graft versus host disease (aGvHD grade I-4) and combined treatment-related toxicity (TRT) (p≤0.003).

In conclusion, this study has replicated and provided additional evidence for the association of GSTA1 with BU PK and clinical outcomes of HSCT. GSTA1 diplotypes can explain in some models ~20% of the variability seen in BU CL and can contribute to HSCT-related complications acting within and beyond BU metabolism. Genotyping therefore may be helpful in deciding the first BU dose, thus decreasing consequences like TRT due to inaccurate first and subsequent dosing. This may be particularly important for GSTA1 diplotype Group IV carriers.

Disclosures

Bittencourt: Jazz Pharmaceuticals: Consultancy, Other: Educational Grant; Seattle Genetics: Consultancy.